Peptides are
pharmacology.

A peptide is a short chain of amino acids — typically between 2 and 50. Once a chain gets longer than about 50, we call it a protein. There's no hard biochemical line; the distinction is conventional.

Many of the compounds Pepra dispenses are fragments of proteins your body already produces. BPC-157 is a fragment of a protein in human gastric juice. TB-500 is a fragment of thymosin β-4, an actin-binding protein in nearly every cell. Semax is a fragment of ACTH (adrenocorticotropic hormone). GHK-Cu is a tripeptide that occurs naturally in human plasma.

This is why peptides tend to act on relatively specific pathways with relatively narrow side-effect profiles. They are designed by evolution to do one or two things; we are using them to do those things.

This is the most common confusion, and it matters legally and clinically.

A dietary supplement is regulated under DSHEA (1994) — it can be sold over the counter without proving safety or efficacy, as long as the manufacturer doesn't make disease claims. The FDA's role is reactive: pull a product if it harms people, otherwise stay out of the way.

A peptide therapy is regulated as a drug. Either it's an FDA-approved finished drug (rare for the compounds we work with), or it's a compounded medication prepared under a valid prescription by a licensed pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. Either way, you need a prescription. There is no over-the-counter pathway for the compounds in the Pepra catalog.

If a website is selling you BPC-157 or TB-500 without a prescription, they're either selling something labeled "for research use only" — which has its own regulatory and quality concerns — or they are operating outside of US law.

Under 503A compounding, the FDA maintains a list of bulk drug substances that compounding pharmacies can use. Substances on that list are considered Category 1 — eligible for compounding while under FDA review, with no objections raised.

In late 2023, the FDA placed several peptide active ingredients — including BPC-157, MOTS-c, and some others — into Category 2 pending additional safety evaluation. Compounding pharmacies could no longer dispense those compounds while they remained in Category 2.

That review is now resolving. Through 2025 and into early 2026, the FDA has been moving compounds back to Category 1 as evidence is reviewed. Pepra exists in this transition window — to make sure that the people who need these compounds can get them through a real clinical pathway, with real prescribers and real pharmacies.

We only dispense compounds with current Category 1 status. If a compound's status changes, we transition affected patients to a clinically appropriate alternative.

Honesty about evidence is core to the brand. The reality is that the catalog spans a range:

Strongly evidenced.

GLP-1 receptor agonists (semaglutide, tirzepatide) — large randomized controlled trials, FDA-approved branded versions, hundreds of thousands of patient-years of clinical use, established cardiovascular outcome data.

Well-evidenced for specific indications.

GHK-Cu — multiple controlled topical dermatology trials with measurable endpoints; long history of inclusion in cosmetics and clinical wound-care preparations.

Robust preclinical, maturing human evidence.

BPC-157, TB-500, CJC-1295, Ipamorelin — strong animal data (in some cases spanning three decades), with human trials at smaller scale and earlier stages. Mechanistic plausibility is solid; outcome trials are still accumulating.

Long international clinical use, limited Western RCTs.

Semax — decades of clinical use in Russia and CIS countries on a national-essential-medicines list, but published evidence is predominantly in non-English journals, and Western independent replication is limited.

We tell you which is which on every product page. Your prescriber considers evidence quality alongside your individual presentation.

Most peptides are destroyed by stomach acid before they reach circulation. There are exceptions — oral semaglutide exists as a finished product — but for the compounds in our catalog, oral delivery would mean digesting your medicine.

That's why nearly all Pepra protocols are subcutaneous injection. The injection sites are the thigh, abdomen, or upper arm; the syringes are insulin syringes (29-gauge or 31-gauge), the same kind diabetic patients use multiple times a day.

Some compounds — Semax, GHK-Cu — also have intranasal or topical routes. We discuss the trade-offs on each product page.

Your first cold-shipped package includes a one-page primer for reconstituting the lyophilized peptide and self-administering. Most patients say their first injection is the only nervous one. The pharmacy includes a sharps return mailer for safe disposal.

We don't sell research chemicals. Compounds labeled "for research use only" exist in a gray market with quality and identity concerns. That's not Pepra.

We don't ship internationally. Our prescriber network is licensed in US states; our pharmacy partners ship within those states. International shipping creates regulatory issues we won't take on.

We don't treat anyone under 25. Peptide pharmacology in adolescents and young adults is under-studied and poorly characterized. We refer young patients back to their pediatricians or primary care.

We don't dispense recombinant human growth hormone. Despite the secretagogue protocol (CJC-1295 / Ipamorelin) sometimes being confused with rHGH, the two are fundamentally different — different pharmacology, different risks, different regulatory status. rHGH for adults is restricted to specific medical indications and is outside our scope.

We don't oversell. Some compounds will not work for some patients. Our intake notes show a meaningful subset of patients consider Semax "not for them" by week 4. We don't lock you in.